PL2516425T3 - Inhibitory kinaz aminopirydynowych - Google Patents
Inhibitory kinaz aminopirydynowychInfo
- Publication number
- PL2516425T3 PL2516425T3 PL10805355T PL10805355T PL2516425T3 PL 2516425 T3 PL2516425 T3 PL 2516425T3 PL 10805355 T PL10805355 T PL 10805355T PL 10805355 T PL10805355 T PL 10805355T PL 2516425 T3 PL2516425 T3 PL 2516425T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- aminopyrimidine
- aminopyrimidine kinase
- inhibitors
- kinase
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28968509P | 2009-12-23 | 2009-12-23 | |
| US32448110P | 2010-04-15 | 2010-04-15 | |
| EP10805355.4A EP2516425B1 (en) | 2009-12-23 | 2010-12-23 | Aminopyrimidine kinase inhibitors |
| PCT/US2010/062024 WO2011079274A1 (en) | 2009-12-23 | 2010-12-23 | Aminopyrimidine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2516425T3 true PL2516425T3 (pl) | 2016-03-31 |
Family
ID=43585673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10805355T PL2516425T3 (pl) | 2009-12-23 | 2010-12-23 | Inhibitory kinaz aminopirydynowych |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8563539B2 (pl) |
| EP (1) | EP2516425B1 (pl) |
| JP (1) | JP5793505B2 (pl) |
| KR (1) | KR101858097B1 (pl) |
| CN (1) | CN102884062B (pl) |
| AU (1) | AU2010336386B2 (pl) |
| BR (1) | BR112012015248B1 (pl) |
| CA (1) | CA2783575C (pl) |
| ES (1) | ES2555224T3 (pl) |
| IL (1) | IL220212A (pl) |
| MX (1) | MX2012007191A (pl) |
| PL (1) | PL2516425T3 (pl) |
| RU (1) | RU2636589C2 (pl) |
| WO (1) | WO2011079274A1 (pl) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| BR112012015248B1 (pt) * | 2009-12-23 | 2022-01-04 | Jasco Pharmaceuticals, LLC | Composto |
| WO2011103289A2 (en) * | 2010-02-17 | 2011-08-25 | Jasco Pharmaceuticals, LLC | Imidazole-2, 4-dione inhibitors of casein kinase 1 |
| MX2012010557A (es) * | 2010-03-16 | 2012-10-05 | Merck Patent Gmbh | Morfolinilquinazolinas. |
| WO2012145581A1 (en) * | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| WO2012145617A2 (en) * | 2011-04-22 | 2012-10-26 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| EP2776432B1 (en) | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| JP6023630B2 (ja) * | 2013-04-03 | 2016-11-09 | 株式会社ヤクルト本社 | チアゾロン誘導体 |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| HRP20220642T1 (hr) | 2016-03-10 | 2022-06-24 | Janssen Pharmaceutica Nv | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 |
| MA45244A (fr) | 2016-06-13 | 2019-04-17 | Cancer Research Tech Ltd | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| CA3083000A1 (en) * | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN109988170B (zh) * | 2017-12-29 | 2022-04-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| WO2019209962A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| AU2019289966A1 (en) * | 2018-06-20 | 2020-12-17 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| CN109223758A (zh) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴类stat3抑制剂联合用药物组合物 |
| CN109369627A (zh) * | 2018-10-31 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 芴酮类stat3抑制剂晶型a及制备方法 |
| CN109331004A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物 |
| CN109172563A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物 |
| CN109846888A (zh) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物 |
| CN109180657A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Stat3抑制剂的制备方法 |
| CN109336868A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 吲哚类stat3抑制剂及其制备方法 |
| CN109200044A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物 |
| CN109485643A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴酮类stat3抑制剂及制备方法与应用 |
| CN109293641A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴类stat3抑制剂及其制备方法 |
| CN109966297A (zh) * | 2018-10-31 | 2019-07-05 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物 |
| CN109288847A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物 |
| CN109288845A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法 |
| CN109288846A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物 |
| CN109200052A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物 |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2024026484A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| JP2026509318A (ja) | 2022-10-31 | 2026-03-18 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | 骨髄増殖性新生物を治療するためのｐｉｍ１阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ181493A3 (en) * | 1992-09-10 | 1994-03-16 | Lilly Co Eli | The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease |
| TW245716B (pl) * | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
| US5955481A (en) * | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| IL113112A (en) | 1994-03-28 | 2000-06-01 | Nissan Chemical Ind Ltd | Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them |
| AU712802B2 (en) | 1994-10-20 | 1999-11-18 | Nippon Chemiphar Co. Ltd. | Quinoline derivatives |
| WO2006009734A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| AT7634U1 (de) | 2004-06-29 | 2005-06-27 | Binder Co Ag | Detektiervorrichtung und sortiervorrichtung |
| JP5209311B2 (ja) | 2004-09-03 | 2013-06-12 | メルク セローノ ソシエテ アノニム | ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用 |
| WO2006097341A1 (en) | 2005-03-17 | 2006-09-21 | Synthon B.V. | Process for making crystalline donepezil hydrochloride monohydrate |
| EP1916249A1 (en) * | 2006-10-10 | 2008-04-30 | LEK Pharmaceuticals D.D. | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| WO2009097113A2 (en) * | 2008-01-28 | 2009-08-06 | New York University | Oxazole and thiazole compounds as b-catenin modulators and uses thereof |
| US20100331315A1 (en) | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
| BR112012015248B1 (pt) * | 2009-12-23 | 2022-01-04 | Jasco Pharmaceuticals, LLC | Composto |
| WO2012145617A2 (en) * | 2011-04-22 | 2012-10-26 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2776432B1 (en) * | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
-
2010
- 2010-12-23 BR BR112012015248-3A patent/BR112012015248B1/pt not_active IP Right Cessation
- 2010-12-23 CN CN201080064323.7A patent/CN102884062B/zh not_active Expired - Fee Related
- 2010-12-23 PL PL10805355T patent/PL2516425T3/pl unknown
- 2010-12-23 AU AU2010336386A patent/AU2010336386B2/en not_active Ceased
- 2010-12-23 US US12/978,089 patent/US8563539B2/en not_active Expired - Fee Related
- 2010-12-23 CA CA2783575A patent/CA2783575C/en active Active
- 2010-12-23 MX MX2012007191A patent/MX2012007191A/es active IP Right Grant
- 2010-12-23 RU RU2012131082A patent/RU2636589C2/ru active
- 2010-12-23 JP JP2012546236A patent/JP5793505B2/ja not_active Expired - Fee Related
- 2010-12-23 ES ES10805355.4T patent/ES2555224T3/es active Active
- 2010-12-23 EP EP10805355.4A patent/EP2516425B1/en active Active
- 2010-12-23 KR KR1020127019285A patent/KR101858097B1/ko not_active Expired - Fee Related
- 2010-12-23 WO PCT/US2010/062024 patent/WO2011079274A1/en not_active Ceased
-
2012
- 2012-06-06 IL IL220212A patent/IL220212A/en active IP Right Grant
-
2013
- 2013-09-20 US US14/032,739 patent/US9157077B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110152235A1 (en) | 2011-06-23 |
| KR101858097B1 (ko) | 2018-05-15 |
| JP2013515743A (ja) | 2013-05-09 |
| ES2555224T3 (es) | 2015-12-29 |
| MX2012007191A (es) | 2012-09-12 |
| CA2783575C (en) | 2018-06-05 |
| CN102884062A (zh) | 2013-01-16 |
| AU2010336386A1 (en) | 2012-07-26 |
| WO2011079274A1 (en) | 2011-06-30 |
| CN102884062B (zh) | 2016-08-03 |
| BR112012015248A2 (pt) | 2017-03-07 |
| RU2636589C2 (ru) | 2017-11-24 |
| AU2010336386B2 (en) | 2016-01-21 |
| KR20120108018A (ko) | 2012-10-04 |
| BR112012015248B1 (pt) | 2022-01-04 |
| US8563539B2 (en) | 2013-10-22 |
| JP5793505B2 (ja) | 2015-10-14 |
| US20140080799A1 (en) | 2014-03-20 |
| EP2516425A1 (en) | 2012-10-31 |
| CA2783575A1 (en) | 2011-06-30 |
| IL220212A0 (en) | 2012-07-31 |
| EP2516425B1 (en) | 2015-09-02 |
| US9157077B2 (en) | 2015-10-13 |
| RU2012131082A (ru) | 2014-01-27 |
| IL220212A (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL220212A0 (en) | Aminopyrimidine kinase inhibitors | |
| ZA201204246B (en) | Kinase inhibitors | |
| ZA201203842B (en) | Kinase inhibitors | |
| ZA201004942B (en) | Ptrrolopyrazine kinase inhibitors | |
| ZA201102423B (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| ZA201100344B (en) | Pyrimidine derivatives as kinase inhibitors | |
| ZA201008808B (en) | Novel phenylpyrazinones as kinase inhibitors | |
| IL206358A0 (en) | Pyrrolopyrazine kinase inhibitors | |
| IL214799A0 (en) | P38map kinase inhibitor | |
| ZA201109340B (en) | Pyrimidinones as pi3k inhibitors | |
| PT2231642E (pt) | Pirimidinas como inibidores de quinase | |
| ZA201204138B (en) | Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| IL209258A0 (en) | Pyrrolopyridines as kinase inhibitors | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| EP2396004A4 (en) | SELECTIVE KINASE HEMMER | |
| GB201009731D0 (en) | Kinase inhibitors | |
| IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
| IL232234A0 (en) | Inhibitors of aminopyrimidine kinase | |
| EP2382210A4 (en) | INHIBITORS OF PYRIMIDINEDIAMINE KINASE | |
| ZA201205277B (en) | Sphingosine kinase inhibitors | |
| ZA201205237B (en) | Sphingosine kinase inhibitors | |
| GB0914726D0 (en) | Kinase inhibitors | |
| SI2373647T1 (sl) | Derivati piridazinona |